J&J's Innovative Medicine chair retires Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 7 August, 2026

One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.

presented by Why Amer­i­ca's med­i­cine be­came a na­tion­al se­cu­ri­ty ques­tion

news BlossomHill, Latigo cap four-IPO week with combined $496M haul Peer Review Jennifer Taubert announces retirement from J&J; Takeda's global TYK2 leader exits Replimune melanoma drug snags coveted FDA approval after yearlong clash, two rejections

Aug 19 1:00 pm ET From pilots to production: AI across R&D, safety, regulatory, and clinical sponsored by IBM Aug 27 12:00 pm ET Same molecule, different paths: Where value goes in cross-border dealmaking in a new era sponsored by PharmCube Sep 03 11:00 am ET How leading pharma organizations are putting AI agents to work sponsored by Medable

Scientist, Drug Discovery Data for AI/ML D. E. Shaw Research New York, NY, USA Machine Learning Researchers and Engineers D. E. Shaw Research New York, NY, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

in case you missed it 1. Exclusive: FDA outlines expedited IND pilot plans, seeking to pick up to 10 programs by year-end 2. Judge signs off on Teva's $35M settlement over delayed inhaler generics 3. Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3 4. Intellia says it has found a key clue to its gene editing safety issues 5. Greg Verdine’s LifeMine raises $263M for safer immunosuppressant 6. Tarsus bets $450M on Alkeus’ Stargardt drug 7. Merck KGaA readies tariff refunds worth €40M for life science customers 8. News Briefing Sarepta pushes back Elevidys timeline; Emergent lays off 90 staffers 9. Vedanta gets $60M to finish Phase 3 for C. diff microbiome therapy 10.